NICE turns down Opdivo/Yervoy combo for kidney cancer
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma.
Read More
Author: Selina McKee
Mereo BioPharma and OncoMed propose merger
The UK’s Mereo BioPharma is planning to merge with US group OncoMed Pharmaceuticals.
Read More
AZ’ Imfinzi fails in head and neck cancer trial
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Read More
Mallinckrodt to split business
UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company
Read More
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma.
Read More- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
